The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
MeSH Review

Hepatitis, Chronic

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Hepatitis, Chronic


Psychiatry related information on Hepatitis, Chronic


High impact information on Hepatitis, Chronic


Chemical compound and disease context of Hepatitis, Chronic


Biological context of Hepatitis, Chronic


Anatomical context of Hepatitis, Chronic


Gene context of Hepatitis, Chronic


Analytical, diagnostic and therapeutic context of Hepatitis, Chronic


  1. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. Heathcote, E.J., Shiffman, M.L., Cooksley, W.G., Dusheiko, G.M., Lee, S.S., Balart, L., Reindollar, R., Reddy, R.K., Wright, T.L., Lin, A., Hoffman, J., De Pamphilis, J. N. Engl. J. Med. (2000) [Pubmed]
  2. Functional inactivation but not structural mutation of p53 causes liver cancer. Ueda, H., Ullrich, S.J., Gangemi, J.D., Kappel, C.A., Ngo, L., Feitelson, M.A., Jay, G. Nat. Genet. (1995) [Pubmed]
  3. Increased serum thyroid hormone binding and decreased free hormone in chronic active liver disease. Schussler, G.C., Schaffner, F., Korn, F. N. Engl. J. Med. (1978) [Pubmed]
  4. Fulminant hepatitis associated with hepatitis A virus superinfection in patients with chronic hepatitis C. Vento, S., Garofano, T., Renzini, C., Cainelli, F., Casali, F., Ghironzi, G., Ferraro, T., Concia, E. N. Engl. J. Med. (1998) [Pubmed]
  5. Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B. McKenzie, R., Fried, M.W., Sallie, R., Conjeevaram, H., Di Bisceglie, A.M., Park, Y., Savarese, B., Kleiner, D., Tsokos, M., Luciano, C. N. Engl. J. Med. (1995) [Pubmed]
  6. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. McHutchison, J.G., Gordon, S.C., Schiff, E.R., Shiffman, M.L., Lee, W.M., Rustgi, V.K., Goodman, Z.D., Ling, M.H., Cort, S., Albrecht, J.K. N. Engl. J. Med. (1998) [Pubmed]
  7. Methotrexate for rheumatoid arthritis. Suggested guidelines for monitoring liver toxicity. American College of Rheumatology. Kremer, J.M., Alarcón, G.S., Lightfoot, R.W., Willkens, R.F., Furst, D.E., Williams, H.J., Dent, P.B., Weinblatt, M.E. Arthritis Rheum. (1994) [Pubmed]
  8. Increased depressive ratings in patients with hepatitis C receiving interferon-alpha-based immunotherapy are related to interferon-alpha-induced changes in the serotonergic system. Bonaccorso, S., Marino, V., Puzella, A., Pasquini, M., Biondi, M., Artini, M., Almerighi, C., Verkerk, R., Meltzer, H., Maes, M. Journal of clinical psychopharmacology. (2002) [Pubmed]
  9. The monoethylglycinexylidide test does not impair psychometric performance in patients with chronic hepatitis or cirrhosis. Botta, F., Giannini, E., Fasoli, A., Romagnoli, P., Risso, D., Testa, R. Therapeutic drug monitoring. (2000) [Pubmed]
  10. The clinical significance of macrocytosis. Breedveld, F.C., Bieger, R., van Wermeskerken, R.K. Acta medica Scandinavica. (1981) [Pubmed]
  11. Lamivudine for the treatment of chronic hepatitis B. Verhelst, D., Goffin, E. N. Engl. J. Med. (2000) [Pubmed]
  12. Resolution of chronic hepatitis B after ritonavir treatment in an HIV-infected patient. Velasco, M., Morán, A., Téllez, M.J. N. Engl. J. Med. (1999) [Pubmed]
  13. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group. Davis, G.L., Esteban-Mur, R., Rustgi, V., Hoefs, J., Gordon, S.C., Trepo, C., Shiffman, M.L., Zeuzem, S., Craxi, A., Ling, M.H., Albrecht, J. N. Engl. J. Med. (1998) [Pubmed]
  14. Clinical outcomes after transfusion-associated hepatitis C. Tong, M.J., el-Farra, N.S., Reikes, A.R., Co, R.L. N. Engl. J. Med. (1995) [Pubmed]
  15. Lamivudine for chronic hepatitis B. Bernasconi, E., Battegay, M. N. Engl. J. Med. (1998) [Pubmed]
  16. Corticosteroid-treated chronic active hepatitis in remission: uncertain prognosis of chronic persistent hepatitis. Czaja, A.J., Ludwig, J., Baggenstoss, A.H., Wolf, A. N. Engl. J. Med. (1981) [Pubmed]
  17. Lymphocyte stimulation in hepatitis B infections. Tong, M.J., Wallace, A.M., Peters, R.L., Reynolds, T.B. N. Engl. J. Med. (1975) [Pubmed]
  18. Nonresponse to interferon in chronic hepatitis C: re-treatment redux. Koff, R. JAMA (2001) [Pubmed]
  19. Heterozygous MZ alpha 1-antitrypsin deficiency in adults with chronic active hepatitis and cryptogenic cirrhosis. Hodges, J.R., Millward-Sadler, G.H., Barbatis, C., Wright, R. N. Engl. J. Med. (1981) [Pubmed]
  20. Primary interferon resistance and treatment response in chronic hepatitis C infection: a pilot study. Jessner, W., Gschwantler, M., Steindl-Munda, P., Hofer, H., Watkins-Riedel, T., Wrba, F., Mueller, C., Gangl, A., Ferenci, P. Lancet (2001) [Pubmed]
  21. Interferon alfa therapy for chronic hepatitis B in children: a multinational randomized controlled trial. Sokal, E.M., Conjeevaram, H.S., Roberts, E.A., Alvarez, F., Bern, E.M., Goyens, P., Rosenthal, P., Lachaux, A., Shelton, M., Sarles, J., Hoofnagle, J. Gastroenterology (1998) [Pubmed]
  22. Hepatitis C virus core protein, cytochrome P450 2E1, and alcohol produce combined mitochondrial injury and cytotoxicity in hepatoma cells. Otani, K., Korenaga, M., Beard, M.R., Li, K., Qian, T., Showalter, L.A., Singh, A.K., Wang, T., Weinman, S.A. Gastroenterology (2005) [Pubmed]
  23. HLA A1, B8, DR3 extended haplotypes in autoimmune chronic hepatitis. Tait, B., Mackay, I.R., Board, P., Coggan, M., Emery, P., Eckardt, G. Gastroenterology (1989) [Pubmed]
  24. Effect of corticosteroids on suppressor-cell activity in "autoimmune" and viral chronic active hepatitis. Nouri-Aria, K.T., Hegarty, J.E., Alexander, G.J., Eddleston, A.L., Williams, R. N. Engl. J. Med. (1982) [Pubmed]
  25. Susceptibility to hepatotoxicity in transgenic mice that express a dominant-negative human keratin 18 mutant. Ku, N.O., Michie, S.A., Soetikno, R.M., Resurreccion, E.Z., Broome, R.L., Oshima, R.G., Omary, M.B. J. Clin. Invest. (1996) [Pubmed]
  26. Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B. Boni, C., Bertoletti, A., Penna, A., Cavalli, A., Pilli, M., Urbani, S., Scognamiglio, P., Boehme, R., Panebianco, R., Fiaccadori, F., Ferrari, C. J. Clin. Invest. (1998) [Pubmed]
  27. K-cell-mediated antibody-dependent cellular cytotoxicity in chronic active liver disease. Kawanishi, H., MacDermott, R.P. Gastroenterology (1979) [Pubmed]
  28. Leukocyte migration inhibition in response to biliary antigens in primary biliary cirrhosis, sclerosing cholangitis, and other chronic liver diseases. McFarlane, I.G., Wojcicka, B.M., Tsantoulas, D.C., Portmann, B.C., Eddleston, A.L., Williams, R. Gastroenterology (1979) [Pubmed]
  29. Mutation of human keratin 18 in association with cryptogenic cirrhosis. Ku, N.O., Wright, T.L., Terrault, N.A., Gish, R., Omary, M.B. J. Clin. Invest. (1997) [Pubmed]
  30. The Fgl2/fibroleukin prothrombinase contributes to immunologically mediated thrombosis in experimental and human viral hepatitis. Marsden, P.A., Ning, Q., Fung, L.S., Luo, X., Chen, Y., Mendicino, M., Ghanekar, A., Scott, J.A., Miller, T., Chan, C.W., Chan, M.W., He, W., Gorczynski, R.M., Grant, D.R., Clark, D.A., Phillips, M.J., Levy, G.A. J. Clin. Invest. (2003) [Pubmed]
  31. Tumor necrosis factor receptors in patients with chronic hepatitis B virus infection. Marinos, G., Naoumov, N.V., Rossol, S., Torre, F., Wong, P.Y., Gallati, H., Portmann, B., Williams, R. Gastroenterology (1995) [Pubmed]
  32. Increased intrahepatic messenger RNA expression of interleukins 2, 6, and 8 in human cirrhosis. Napoli, J., Bishop, G.A., McCaughan, G.W. Gastroenterology (1994) [Pubmed]
  33. Associations of chemokine system polymorphisms with clinical outcomes and treatment responses of chronic hepatitis C. Promrat, K., McDermott, D.H., Gonzalez, C.M., Kleiner, D.E., Koziol, D.E., Lessie, M., Merrell, M., Soza, A., Heller, T., Ghany, M., Park, Y., Alter, H.J., Hoofnagle, J.H., Murphy, P.M., Liang, T.J. Gastroenterology (2003) [Pubmed]
  34. Long-term mortality after transfusion-associated non-A, non-B hepatitis. The National Heart, Lung, and Blood Institute Study Group. Seeff, L.B., Buskell-Bales, Z., Wright, E.C., Durako, S.J., Alter, H.J., Iber, F.L., Hollinger, F.B., Gitnick, G., Knodell, R.G., Perrillo, R.P. N. Engl. J. Med. (1992) [Pubmed]
  35. Interferon and ribavirin vs interferon alone in the re-treatment of chronic hepatitis C previously nonresponsive to interferon: A meta-analysis of randomized trials. Cummings, K.J., Lee, S.M., West, E.S., Cid-Ruzafa, J., Fein, S.G., Aoki, Y., Sulkowski, M.S., Goodman, S.N. JAMA (2001) [Pubmed]
  36. Antibody to hepatitis B core antigen in patients with hepatocellular carcinoma. Kubo, Y., Okuda, K., Hashimoto, M., Nagasaki, Y., Ebata, H. Gastroenterology (1977) [Pubmed]
  37. Duration and specificity of antibodies to hepatitis C virus in chronic active hepatitis. Czaja, A.J., Taswell, H.F., Rakela, J., Rabe, D. Gastroenterology (1992) [Pubmed]
WikiGenes - Universities